J Kobiela1, P Spychalski2, G Marvaso3, D Ciardo3, V Dell'Acqua3, F Kraja4, A Błażyńska-Spychalska1, A J Łachiński1, A Surgo3, R Glynne-Jones5, B A Jereczek-Fossa6. 1. Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdansk, Poland. 2. Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdansk, Poland. Electronic address: piotr.spychalski@gumed.edu.pl. 3. Department of Radiotherapy, European Institute of Oncology, Milan, Italy. 4. Department of Oncology, University Hospital Centre "Mother Theresa", Tirana, Albania. 5. Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, HA6 2RN, UK. 6. Department of Radiotherapy, European Institute of Oncology, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Abstract
BACKGROUND: SBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases. MATERIALS AND METHODS: The review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included. RESULTS: For liver LC rates ranged from 50% to 100% after 1 year and 32% to 91% after 2 years. BED range 40.5-262.5 Gy (Gray). For lung LC rates ranged from 62% to 92% after 1 one year and from 53% to 92% after 2 years. BED range 51.3-262.5 Gy. CONCLUSIONS: SBRT of oligometastatic CRC offers high LC with low morbidity and toxicity. It requires more observational studies and randomized trials but available data on clinical efficacy is promising, however not yet matured.
BACKGROUND: SBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases. MATERIALS AND METHODS: The review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included. RESULTS: For liver LC rates ranged from 50% to 100% after 1 year and 32% to 91% after 2 years. BED range 40.5-262.5 Gy (Gray). For lung LC rates ranged from 62% to 92% after 1 one year and from 53% to 92% after 2 years. BED range 51.3-262.5 Gy. CONCLUSIONS: SBRT of oligometastatic CRC offers high LC with low morbidity and toxicity. It requires more observational studies and randomized trials but available data on clinical efficacy is promising, however not yet matured.
Authors: V Dell'Acqua; A Surgo; F Kraja; J Kobiela; Maria Alessia Zerella; P Spychalski; S Gandini; C M Francia; D Ciardo; C Fodor; A M Ferrari; G Piperno; F Cattani; S Vigorito; F Pansini; W Petz; R Orecchia; M C Leonardi; B A Jereczek-Fossa Journal: Clin Exp Metastasis Date: 2019-06-04 Impact factor: 5.150
Authors: Hoon Sik Choi; Bae Kwon Jeong; Ki Mun Kang; Hojin Jeong; Jin Ho Song; In Bong Ha; Oh-Young Kwon Journal: Cancer Res Treat Date: 2020-07-21 Impact factor: 4.679
Authors: C Carbucicchio; B A Jereczek-Fossa; D Andreini; V Catto; G Piperno; E Conte; F Cattani; E Rondi; S Vigorito; C Piccolo; A Bonomi; A Gorini; M Pepa; S Mushtaq; G Fassini; M Moltrasio; F Tundo; G Marvaso; F Veglia; R Orecchia; E Tremoli; C Tondo Journal: J Interv Card Electrophysiol Date: 2020-08-27 Impact factor: 1.900